vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Legacy Housing Corp (LEGH). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $25.5M, roughly 1.5× Legacy Housing Corp). Legacy Housing Corp runs the higher net margin — 32.2% vs -161.8%, a 194.0% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -30.6%). Legacy Housing Corp produced more free cash flow last quarter ($15.7M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Legacy Housing Corp is a prominent U.S.-based manufacturer of affordable manufactured homes, tiny homes, and accessory dwelling units. It mainly caters to low- and middle-income consumers across North America, providing customizable residential solutions, supporting construction materials, and after-sales services for individual and community development clients.
IBRX vs LEGH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $25.5M |
| Net Profit | $-61.9M | $8.2M |
| Gross Margin | 99.0% | 26.4% |
| Operating Margin | -169.0% | 40.4% |
| Net Margin | -161.8% | 32.2% |
| Revenue YoY | 407.0% | -30.6% |
| Net Profit YoY | -4.7% | -43.5% |
| EPS (diluted) | $-0.06 | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $25.5M | ||
| Q3 25 | $32.1M | $28.8M | ||
| Q2 25 | $26.4M | $38.4M | ||
| Q1 25 | $16.5M | $24.3M | ||
| Q4 24 | $7.6M | $36.7M | ||
| Q3 24 | $6.1M | $30.2M | ||
| Q2 24 | — | $31.7M | ||
| Q1 24 | — | $30.8M |
| Q4 25 | $-61.9M | $8.2M | ||
| Q3 25 | $-67.3M | $8.6M | ||
| Q2 25 | $-92.6M | $14.7M | ||
| Q1 25 | $-129.6M | $10.3M | ||
| Q4 24 | $-59.2M | $14.5M | ||
| Q3 24 | $-85.7M | $15.8M | ||
| Q2 24 | — | $16.2M | ||
| Q1 24 | — | $15.1M |
| Q4 25 | 99.0% | 26.4% | ||
| Q3 25 | 99.4% | 20.2% | ||
| Q2 25 | 99.5% | 32.4% | ||
| Q1 25 | 99.6% | 29.2% | ||
| Q4 24 | — | 27.3% | ||
| Q3 24 | — | 29.2% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 33.6% |
| Q4 25 | -169.0% | 40.4% | ||
| Q3 25 | -173.5% | 33.7% | ||
| Q2 25 | -269.8% | 43.8% | ||
| Q1 25 | -390.1% | 47.7% | ||
| Q4 24 | -919.0% | 42.3% | ||
| Q3 24 | -1314.3% | 50.8% | ||
| Q2 24 | — | 50.6% | ||
| Q1 24 | — | 54.3% |
| Q4 25 | -161.8% | 32.2% | ||
| Q3 25 | -209.8% | 30.0% | ||
| Q2 25 | -350.3% | 38.3% | ||
| Q1 25 | -784.9% | 42.3% | ||
| Q4 24 | -783.4% | 39.5% | ||
| Q3 24 | -1404.0% | 52.4% | ||
| Q2 24 | — | 51.1% | ||
| Q1 24 | — | 49.1% |
| Q4 25 | $-0.06 | $0.38 | ||
| Q3 25 | $-0.07 | $0.35 | ||
| Q2 25 | $-0.10 | $0.60 | ||
| Q1 25 | $-0.15 | $0.41 | ||
| Q4 24 | $-0.08 | $0.59 | ||
| Q3 24 | $-0.14 | $0.64 | ||
| Q2 24 | — | $0.65 | ||
| Q1 24 | — | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $528.6M |
| Total Assets | $501.9M | $580.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $8.5M | ||
| Q3 25 | $257.8M | $13.6M | ||
| Q2 25 | $153.7M | $2.6M | ||
| Q1 25 | $61.6M | $3.4M | ||
| Q4 24 | $149.8M | $1.1M | ||
| Q3 24 | $130.4M | $570.0K | ||
| Q2 24 | — | $60.0K | ||
| Q1 24 | — | $621.0K |
| Q4 25 | $-500.5M | $528.6M | ||
| Q3 25 | $-524.3M | $521.6M | ||
| Q2 25 | $-570.7M | $512.8M | ||
| Q1 25 | $-591.4M | $503.7M | ||
| Q4 24 | $-489.1M | $494.0M | ||
| Q3 24 | $-745.1M | $479.3M | ||
| Q2 24 | — | $463.2M | ||
| Q1 24 | — | $450.4M |
| Q4 25 | $501.9M | $580.3M | ||
| Q3 25 | $519.0M | $557.9M | ||
| Q2 25 | $402.1M | $552.0M | ||
| Q1 25 | $303.8M | $544.6M | ||
| Q4 24 | $382.9M | $534.2M | ||
| Q3 24 | $364.6M | $521.4M | ||
| Q2 24 | — | $514.9M | ||
| Q1 24 | — | $510.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $19.0M |
| Free Cash FlowOCF − Capex | $-71.3M | $15.7M |
| FCF MarginFCF / Revenue | -186.2% | 61.6% |
| Capex IntensityCapex / Revenue | 2.4% | 13.1% |
| Cash ConversionOCF / Net Profit | — | 2.32× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $28.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $19.0M | ||
| Q3 25 | $-68.9M | $7.2M | ||
| Q2 25 | $-79.7M | $6.1M | ||
| Q1 25 | $-85.9M | $4.9M | ||
| Q4 24 | $-85.1M | $7.9M | ||
| Q3 24 | $-98.8M | $13.8M | ||
| Q2 24 | — | $3.5M | ||
| Q1 24 | — | $10.8M |
| Q4 25 | $-71.3M | $15.7M | ||
| Q3 25 | $-69.6M | $5.1M | ||
| Q2 25 | $-80.8M | $3.7M | ||
| Q1 25 | $-87.0M | $3.6M | ||
| Q4 24 | $-87.3M | $6.0M | ||
| Q3 24 | $-101.6M | $9.1M | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | -186.2% | 61.6% | ||
| Q3 25 | -217.2% | 17.8% | ||
| Q2 25 | -305.9% | 9.6% | ||
| Q1 25 | -526.9% | 15.0% | ||
| Q4 24 | -1155.4% | 16.4% | ||
| Q3 24 | -1663.2% | 30.2% | ||
| Q2 24 | — | 5.4% | ||
| Q1 24 | — | 32.2% |
| Q4 25 | 2.4% | 13.1% | ||
| Q3 25 | 2.3% | 7.1% | ||
| Q2 25 | 4.1% | 6.2% | ||
| Q1 25 | 6.8% | 5.2% | ||
| Q4 24 | 28.0% | 5.1% | ||
| Q3 24 | 45.7% | 15.6% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 2.8% |
| Q4 25 | — | 2.32× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.54× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IBRX
Segment breakdown not available.
LEGH
| Commercial Sales | $8.6M | 34% |
| Retail Store Sales | $6.0M | 24% |
| Inventory Finance Sales | $5.0M | 20% |
| Direct Sales | $4.4M | 17% |
| Other | $1.5M | 6% |
